Effects of BDNF polymorphisms on antidepressant action
Shih-Jen Tsai1, Chen-Jee Hong, Ying-Jay Liou
1Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Psychiatry Investigation
|January 22, 2011
Summary
Brain-derived neurotrophic factor (BDNF) signaling is crucial for major depression. The Val66Met polymorphism in the BDNF gene may influence antidepressant response, particularly in Asian populations.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Major depression is linked to reduced brain-derived neurotrophic factor (BDNF) signaling.
- Antidepressant treatments may restore BDNF activity, contributing to therapeutic effects.
- Genetic factors influence individual responses to antidepressants.
Purpose of the Study:
- To investigate the association between the BDNF Val66Met polymorphism and antidepressant treatment response.
- To synthesize existing pharmacogenetic data on BDNF and depression.
Main Methods:
- Meta-analysis of eight pharmacogenetic studies.
- Inclusion of data from 1,115 subjects.
- Analysis of the BDNF Val66Met polymorphism (rs6265).
Main Results:
- A meta-analysis suggested that carriers of the Val66Met polymorphism (heterozygotes) show enhanced antidepressant response compared to Val/Val homozygotes.
- This effect was more pronounced in the Asian population.
- Results support a potential positive molecular heterosis effect for BDNF in depression treatment.
Conclusions:
- The BDNF Val66Met polymorphism may be a predictor of antidepressant response.
- Further research should explore haplotype approaches, gene-gene interactions, and specific symptom clusters for a comprehensive understanding.
- Recommendations for future pharmacogenetic studies of BDNF are proposed.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...